Choose Your Country or Region

Sodium butyrate

Name: Sodium butyrate
Brand: Selleck Chemicals
SKU: S1999
Rating: 5 (19 reviews)

Catalog No.S1999 Synonyms: NaB, Butanoic acid sodium salt

For research use only.

Sodium butyrate (NaB, Butanoic acid sodium salt), sodium salt of butyric acid, is a histone deacetylase inhibitor and competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). Sodium butyrate (NaB) inhibits cell cycle progression, promotes differentiation, and induces apoptosis and autophagy in several types of cancer cells.

CAS No. 156-54-7

Selleck's Sodium butyrate has been cited by 19 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Related Compound Libraries

Other HDAC Products

CAY10603^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202)^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683, Zolinza) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Download Inhibitor Catalog

HDAC Signaling Pathway Map

Biological Activity

Description

Targets

Histone deacetylase ^[6]

In vitro

Butyrate mediates growth inhibition of colonic cancer cells and thereby to elucidate the molecular link between a high-fiber diet and the arrest of colon carcinogenesis. Butyrate induces p21 mRNA expression in an immediate-early fashion, through transactivation of a promoter cis-element(s) located within 1.4 kb of the transcriptional start site, independent of p53 binding. ^[1] Sodium butyrate, at physiological concentrations, induces apoptosis in 2 adenoma cell lines, RG/C2 and AA/Cl, and in the carcinoma cell line PC/JW/FI. ^[2] Butyrate exerts potent effects on a variety of colonic mucosal functions such as inhibition of inflammation and carcinogenesis, reinforcing various components of the colonic defence barrier and decreasing oxidative stress. ^[3] Butyrate inhibits most HDAC except class III HDAC and class II HDAC6 and -10. Butyrate also is the most effective fatty acid in stimulating or repressing the expression of specific genes. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human K562 cells	NVXnbHh[WHKxbHnm[ZJifGmxbjDhd5NigQ>?	M3TCblEhdU1?		MljQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|IHH0JFEhdU1iaX6gdJJme2WwY3Wgc4Yh\3Wjbn;zbY5m	NFP1R5IzOzl\|N{m3PS=>
human H1299 cells	MUDGeY5kfGmxbjDhd5NigQ>?		MYi3JIRigXN?	Moq3TY5pcWKrdHnvckBw\iCqdX3hckBWW1BzL2XBSlEhcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOxbH;ufUBnd3KvYYTpc44h[W[2ZYKgO{Bl[Xm\|LDDFR\|UxRTNizszN	NFz6dZkzPTJ{OU[0Ny=>
human JEG3 cells	MnXQSpVv[3Srb36gZZN{[Xl?			M1ntbmlvcGmkaYTpc44hd2ZiYYLvcYF1[XOnIHnuJIh2dWGwIFrFS\|Mh[2WubIOgZpkhe2OrboTpcIxifGmxbjDzdIVkfHKxbXX0dpktKEmFNUC9NE4xODF3IN88US=>	M1PPZVIxOTR6NU[0

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	Cyclin D3 / CDK4 / CDK6 / CDK2 ; p15INK4b / p21Cip1 ; Phospho-H3 Ser10 / Acetyl-H3Lys9 / Acetyl-H3Lys14 / Dimethyl-H3	24280698
Immunofluorescence	Acetyl-H3Lys9	24280698

In vivo

Sodium butyrate significantly extends survival in a dose-dependent manner, improves body weight and motor performance, and delays the neuropathological sequelae in the R6/2 transgenic mouse model of Huntington's disease (HD). Sodium butyrate also increases histone and specificity protein-1 acetylation and protects against 3-nitropropionic acid neurotoxicity. ^[5]

Protocol (from reference)

References

+ Expand

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	110.09
Formula	C₄H₇NaO₂
CAS No.	156-54-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CCCC(=O)[O-].[Na+]

Download Sodium butyrate SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00800930	Completed	Biological: Sodium Butyrate\|Biological: Saline	Shigellosis	International Centre for Diarrhoeal Disease Research Bangladesh\|Swedish International Development Cooperation Agency (SIDA)\|Karolinska Institutet	January 2005	Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):